Recent news on

Velcade® plus Doxil® Approved for Multiple Myeloma  -  May 23, 2007
Cancer Consultants (press release),...(FDA) recently approved the treatment combination consisting of Velcade® (bortezomib) plus Doxil® (doxorubicin HCl liposome injection) for the treatment

US FDA Approves VELCADE(R) + DOXIL(R) Combination for Treatment of ...  -  May 21, 2007
PR Newswire (press release),LP, today announced the US Food and Drug Administration (FDA) has approved the use of DOXIL(R) (doxorubicin HCl liposome injection) in combination with

FDA approves VELCADE plus DOXIL combination for multiple myeloma  -  May 23, 2007
News-Medical.net,Ortho Biotech Products has announced the US Food and Drug Administration (FDA) has approved the use of DOXIL (doxorubicin HCl liposome injection) in

Supplemental New Drug Application Accepted for Doxil® Plus Velcade ...  -  Feb 6, 2007
Cancer Consultants (press release),...(pegylated doxorubicin HCl liposome injection) in combination with Velcade (bortezomib) for the treatment of relapsed or refractory multiple myeloma.

Interim Analysis Finds DOXIL(R)/VELCADE(R) Combination ...  -  Dec 11, 2006
PR Newswire (press release),11 /PRNewswire-FirstCall/ -- Researchers investigating the combination of DOXIL(R) (doxorubicin HCl liposome injection) and VELCADE(R) (bortezomib),

Interim Analysis Finds DOXIL(R)/VELCADE(R) Combination ...  -  Dec 11, 2006
Earthtimes.org11 -- Researchers investigating the combination of DOXIL(R) (doxorubicin HCl liposome injection) and VELCADE(R) (bortezomib), the market leader in relapsed

Interim Analysis Finds Doxil/Velcade Combination Significantly ...  -  Dec 11, 2006
PharmaLive.com (press release),ORLANDO, Fla., December 11, 2006 /PRNewswire-FirstCall/ -- Researchers investigating the combination of DOXIL(R) (doxorubicin HCl liposome injection) and

Delivering on Nano's Promise  Oct 9, 2006
In 1995, several years before the word nanotechnology began creating a buzz, Doxil (doxorubicin HCL liposome injection) received accelerated approval for the ... -Drug Discovery & Development, Interim Analysis Finds DOXIL(R)/VELCADE(R) Combination ...  -  Dec 11, 2006
PR Newswire (press release),11 /PRNewswire-FirstCall/ -- Researchers investigating the combination of DOXIL(R) (doxorubicin HCl liposome injection) and VELCADE(R) (bortezomib),



CA-125 May Not Be Reliable Marker for Response to Doxil® In ...  May 3, 2006
...meeting on Women’s Cancer™, early CA-125 levels were not consistently reliable as a measure of response to Doxil® (doxorubicin HCl liposome injection) in ... - Cancer Consultants

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional